1
|
Al Mohammad B, Brennan PC and Mello-Thoms
C: A review of lung cancer screening and the role of computer-aided
detection. Clin Radiol. 72:433–442. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Zhu B, Qi L, Liu S, Liu W, Ou Z, Chen M,
Liu L, Zu X, Wang J and Li Y: CLASP2 is involved in the EMT and
early progression after transurethral resection of the bladder
tumor. BMC Cancer. 17:1052017. View Article : Google Scholar : PubMed/NCBI
|
3
|
He YX, Song XH, Zhao ZY and Zhao H: HOXA13
upregulation in gastric cancer is associated with enhanced cancer
cell invasion and epithelial-to-mesenchymal transition. Eur Rev Med
Pharmacol Sci. 21:258–265. 2017.PubMed/NCBI
|
4
|
Chen J, Zhang H, Chen Y, Qiao G, Jiang W,
Ni P, Liu X and Ma L: miR-598 inhibits metastasis in colorectal
cancer by suppressing JAG1/Notch2 pathway stimulating EMT. Exp Cell
Res. 352:104–112. 2017. View Article : Google Scholar : PubMed/NCBI
|
5
|
Feng H, Lu JJ, Wang Y, Pei L and Chen X:
Osthole inhibited TGF β-induced epithelial-mesenchymal transition
(EMT) by suppressing NF-κB mediated Snail activation in lung cancer
A549 cells. Cell Adhes Migr. Feb 1–2017.(Epub ahead of print).
View Article : Google Scholar
|
6
|
Xu J, Zhang X, Wang H, Ge S, Gao T, Song
L, Wang X, Li H, Qin Y and Zhang Z: HCRP1 downregulation promotes
hepatocellular carcinoma cell migration and invasion through the
induction of EGFR activation and epithelial-mesenchymal transition.
Biomed Pharmacother. 88:421–429. 2017. View Article : Google Scholar : PubMed/NCBI
|
7
|
Yeung KT and Yang J:
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol.
11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
8
|
Otto W, Breyer J, Herdegen S, Eder F,
Bertz S, May M, Mayr R, Lausenmeyer EM, Denzinger S, van Rhijn BW,
et al: WHO 1973 grade 3 and infiltrative growth pattern proved,
aberrant E-cadherin expression tends to be of predictive value for
progression in a series of stage T1 high-grade bladder cancer after
organ-sparing approach. Int Urol Nephrol. 49:431–437. 2017.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Li Z, Yin S, Zhang L, Liu W and Chen B:
Prognostic value of reduced E-cadherin expression in breast cancer:
A meta-analysis. Oncotarget. 8:16445–16455. 2017.PubMed/NCBI
|
10
|
Tran YK, Bögler O, Gorse KM, Wieland I,
Green MR and Newsham IF: A novel member of the NF2/ERM/4.1
superfamily with growth suppressing properties in lung cancer.
Cancer Res. 59:35–43. 1999.PubMed/NCBI
|
11
|
Li L, Li S, Cai T, Wang H, Xie X, Liu Z
and Zhang Y: The targeted inhibitory effects of human amniotic
fluid stem cells carrying CXCR4 promoter and DAL-1 on non-small
cell lung carcinoma growth. Gene Ther. 23:214–222. 2016. View Article : Google Scholar : PubMed/NCBI
|
12
|
Takahashi Y, Iwai M, Kawai T, Arakawa A,
Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F, et al:
Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive
lesions of primary breast cancer. Breast Cancer. 19:242–252. 2012.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Wang H, Xu M, Cui X, Liu Y, Zhang Y, Sui
Y, Wang D, Peng L, Wang D and Yu J: Aberrant expression of the
candidate tumor suppressor gene DAL-1 due to hypermethylation in
gastric cancer. Sci Rep. 6:217552016. View Article : Google Scholar : PubMed/NCBI
|
14
|
Nagata M, Sakurai-Yageta M, Yamada D, Goto
A, Ito A, Fukuhara H, Kume H, Morikawa T, Fukayama M, Homma Y, et
al: Aberrations of a cell adhesion molecule CADM4 in renal clear
cell carcinoma. Int J Cancer. 130:1329–1337. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Dafou D, Grun B, Sinclair J, Lawrenson K,
Benjamin EC, Hogdall E, Kruger-Kjaer S, Christensen L, Sowter HM,
Al-Attar A, et al: Microcell-mediated chromosome transfer
identifies EPB41L3 as a functional suppressor of epithelial ovarian
cancers. Neoplasia. 12:579–89. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Kittiniyom K, Mastronardi M, Roemer M,
Wells WA, Greenberg ER, Titus-Ernstoff L and Newsham IF:
Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3)
tumor-suppressor gene locus in the absence of mutation. Genes
Chromosomes Cancer. 40:190–203. 2004. View Article : Google Scholar : PubMed/NCBI
|
17
|
Chen X, Guan X, Zhang H, Xie X, Wang H,
Long J, Cai T, Li S, Liu Z and Zhang Y: DAL-1 attenuates
epithelial-to mesenchymal transition in lung cancer. J Exp Clin
Cancer Res. 34:32015. View Article : Google Scholar : PubMed/NCBI
|
18
|
Moreno JA and Tiffany-Castiglioni E: The
chaperone Grp78 in protein folding disorders of the nervous system.
Neurochem Res. 40:329–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
19
|
Yu T, Guo Z, Fan H, Song J, Liu Y, Gao Z
and Wang Q: Cancer-associated fibroblasts promote non-small cell
lung cancer cell invasion by upregulation of glucose-regulated
protein 78 (GRP78) expression in an integrated bionic microfluidic
device. Oncotarget. 7:25593–25603. 2016. View Article : Google Scholar : PubMed/NCBI
|
20
|
Chen HA, Chang YW, Tseng CF, Chiu CF, Hong
CC, Wang W, Wang MY, Hsiao M, Ma JT, Chen CH, et al: E1A-mediated
inhibition of HSPA5 suppresses cell migration and invasion in
triple-negative breast cancer. Ann Surg Oncol. 22:889–898. 2015.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra
SK, Krasnoperov V, Dong D, Liu S, Li D, et al: Monoclonal antibody
against cell surface GRP78 as a novel agent in suppressing PI3K/AKT
signaling, tumor growth, and metastasis. Clin Cancer Res.
19:6802–6811. 2013. View Article : Google Scholar : PubMed/NCBI
|
22
|
Dekervel J, Bulle A, Windmolders P,
Lambrechts D, Van Cutsem E, Verslype C and van Pelt J: Acriflavine
inhibits acquired drug resistance by blocking the
epithelial-to-mesenchymal transition and the unfolded protein
response. Transl Oncol. 10:59–69. 2017. View Article : Google Scholar : PubMed/NCBI
|
23
|
Xu J, Liu D, Niu H, Zhu G, Xu Y, Ye D, Li
J and and Zhang Q: Resveratrol reverses Doxorubicin resistance by
inhibiting epithelial-mesenchymal transition (EMT) through
modulating PTEN/Akt signaling pathway in gastric cancer. J Exp Clin
Cancer Res. 36:192017. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhang Y, Xu R, Li G, Xie X, Long J and
Wang H: Loss of expression of the differentially expressed in
adenocarcinoma of the lung (DAL-1) protein is associated with
metastasis of non-small cell lung carcinoma cells. Tumour Biol.
33:1915–1925. 2012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Sun Q, Hua J, Wang Q, Xu W, Zhang J, Zhang
J, Kang J and Li M: Expressions of GRP78 and Bax associate with
differentiation, metastasis, and apoptosis in non-small cell lung
cancer. Mol Biol Rep. 39:6753–6761. 2012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Wu HM, Jiang ZF, Fan XY, Wang T, Ke Xu,
Yan XB, Ma Y, Xiao WH and Liu RY: Reversed expression of GRIM-1 and
GRP78 in human non-small cell lung cancer. Hum Pathol.
45:1936–1943. 2014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Busam RD, Thorsell AG, Flores A,
Hammarström M, Persson C, Öbrink B and Hallberg BM: Structural
basis of tumor suppressor in lung cancer 1 (TSLC1) binding to
differentially expressed in adenocarcinoma of the lung
(DAL-1/4.1B). J Biol Chem. 286:4511–4516. 2011. View Article : Google Scholar : PubMed/NCBI
|
28
|
Singh V, Miranda TB, Jiang W, Frankel A,
Roemer ME, Robb VA, Gutmann DH, Herschman HR, Clarke S and Newsham
IF: DAL-1/4.1B tumor suppressor interacts with protein arginine
N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate
substrates in vitro and in vivo. Oncogene. 23:7761–7771. 2004.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Horresh I, Bar V, Kissil JL and Peles E:
Organization of myelinated axons by Caspr and Caspr2 requires the
cytoskeletal adapter protein 4.1B. J Neurosci. 30:2480–2489. 2010.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Kamijo A, Saitoh Y, Ohno N, Ohno S and
Terada N: Immunohistochemical study of the membrane skeletal
protein, membrane protein palmitoylated 6 (MPP6), in the mouse
small intestine. Histochem Cell Biol. 145:81–92. 2016. View Article : Google Scholar : PubMed/NCBI
|
31
|
Jiang W, Roemer ME and Newsham IF: The
tumor suppressor DAL-1/4.1B modulates protein arginine
N-methyltransferase 5 activity in a substrate-specific manner.
Biochem Biophys Res Commun. 329:522–530. 2005. View Article : Google Scholar : PubMed/NCBI
|
32
|
Robb VA, Gerber MA, Hart-Mahon EK and
Gutmann DH: Membrane localization of the U2 domain of Protein 4.1B
is necessary and sufficient for meningioma growth suppression.
Oncogene. 24:1946–1957. 2005. View Article : Google Scholar : PubMed/NCBI
|
33
|
McCarty JH, Cook AA and Hynes RO: An
interaction between {alpha}v{beta}8 integrin and Band 4.1B via a
highly conserved region of the Band 4.1 C-terminal domain. Proc
Natl Acad Sci USA. 102:pp. 13479–13483. 2005; View Article : Google Scholar : PubMed/NCBI
|
34
|
Zhang L, Zhu S, Shi X and Sha W: The
silence of p66(Shc) in HCT8 cells inhibits the viability via
PI3K/AKT/Mdm-2/p53 signaling pathway. Int J Clin Exp Pathol.
8:9097–9104. 2015.PubMed/NCBI
|